JYONG BIOTECH LTD

MENSNASDAQ

🏆 #3212 by market capUS Equity

$2.13▲ $0.07 (+3.16%)

Pre-market · at close

1h—

24h▲ 3.2%

7d▲ 2.7%

14d▼ 8.8%

30d▼ 2.5%

1y▼ 95.3%

🏦Market Cap

$162M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

—

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $2.10 – $2.14
52-Week Range: $1.43 – $67.00
Volume: $2.71B
Avg Volume: $3.41B
Shares Outstanding: 76.0M
Next Earnings: Sep 1, 2026

Fundamentals Snapshot

Annual Revenue: $43M
Last Q Revenue: $10M
P/E Ratio: -24.3
P/S Ratio: 0.0x
EPS (TTM): $-0.06
Dividend Yield: 0.00%

Why Investors Own MENS

✓High-growth profile — revenue up +37.2% YoY with expanding US Equity exposure.
✓Healthy economics — 33% gross margin and 9% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$43M▲ +34.9% YoY

Gross Margin (TTM)

33.4%▲ +0.0% YoY

Operating Income (TTM)

$12M▲ +34.9% YoY

Free Cash Flow (TTM)

$4M▲ +34.9% YoY

About JYONG BIOTECH LTD

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

🦦